[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20024099L - Lavdose entecavir-formulering og anvendelse - Google Patents

Lavdose entecavir-formulering og anvendelse

Info

Publication number
NO20024099L
NO20024099L NO20024099A NO20024099A NO20024099L NO 20024099 L NO20024099 L NO 20024099L NO 20024099 A NO20024099 A NO 20024099A NO 20024099 A NO20024099 A NO 20024099A NO 20024099 L NO20024099 L NO 20024099L
Authority
NO
Norway
Prior art keywords
low dose
dose entecavir
entecavir formulation
formulation
low
Prior art date
Application number
NO20024099A
Other languages
English (en)
Other versions
NO20024099D0 (no
NO324014B1 (no
Inventor
Richard J Colonno
Omar L Sprockel
Abizer Harianawala
Divyakant Desai
Michael G Fakes
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024099(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20024099L publication Critical patent/NO20024099L/no
Publication of NO20024099D0 publication Critical patent/NO20024099D0/no
Publication of NO324014B1 publication Critical patent/NO324014B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20024099A 2000-02-29 2002-08-28 Farmasøytisk preparat omfattende lavdose entecavir, samt fremstilling derav NO324014B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29
US22131300P 2000-07-28 2000-07-28
PCT/US2001/002630 WO2001064221A1 (en) 2000-02-29 2001-01-26 Low dose entecavir formulation and use

Publications (3)

Publication Number Publication Date
NO20024099L true NO20024099L (no) 2002-08-28
NO20024099D0 NO20024099D0 (no) 2002-08-28
NO324014B1 NO324014B1 (no) 2007-07-30

Family

ID=26881354

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024099A NO324014B1 (no) 2000-02-29 2002-08-28 Farmasøytisk preparat omfattende lavdose entecavir, samt fremstilling derav

Country Status (35)

Country Link
US (1) US6627224B2 (no)
EP (2) EP1267880B2 (no)
JP (3) JP5140222B2 (no)
KR (1) KR100757155B1 (no)
AR (1) AR027965A1 (no)
AT (1) ATE312613T1 (no)
AU (1) AU2001229775A1 (no)
BG (1) BG65815B1 (no)
BR (1) BRPI0108435B8 (no)
CA (1) CA2401569C (no)
CO (1) CO5261593A1 (no)
CZ (1) CZ303395B6 (no)
DE (1) DE60115870T3 (no)
DK (1) DK1267880T4 (no)
EA (1) EA006181B1 (no)
EE (1) EE05442B1 (no)
EG (1) EG24408A (no)
ES (1) ES2253403T5 (no)
GE (1) GEP20053504B (no)
HK (1) HK1048771A1 (no)
HR (1) HRP20020649A2 (no)
HU (1) HU230698B1 (no)
IL (1) IL150447A0 (no)
MX (1) MXPA02008359A (no)
MY (1) MY127422A (no)
NO (1) NO324014B1 (no)
NZ (1) NZ520024A (no)
PE (1) PE20020770A1 (no)
PL (1) PL201411B1 (no)
RS (1) RS51561B (no)
SI (1) SI1267880T2 (no)
SK (1) SK288008B6 (no)
TW (1) TWI287988B (no)
UA (1) UA84534C2 (no)
WO (1) WO2001064221A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1267880B2 (en) * 2000-02-29 2010-01-20 Bristol-Myers Squibb Company Low dose entecavir formulation and use
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ES2397104T3 (es) 2002-12-11 2013-03-04 Bristol-Myers Squibb Company Procedimiento y productos intermedios para la síntesis de entecavir
AP2089A (en) 2003-01-14 2010-01-11 Gilead Sciences Inc Compositions and methods for combination antiviraltherapy
DK3138566T3 (da) 2003-11-17 2022-01-31 Biomarin Pharm Inc Behandling af phenylketonuri med bh4
EP1686965A2 (de) * 2003-11-18 2006-08-09 Boehringer Ingelheim International GmbH Feste pharmazeutische zubereitungsform
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP4756153B2 (ja) * 2004-08-27 2011-08-24 富士製薬工業株式会社 低成分含量の錠剤の製造方法
BRPI0515416A (pt) * 2004-09-23 2008-07-22 Fmc Corp composição, forma sólida, filme, e, método para revestir uma forma sólida
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
US8367104B2 (en) * 2009-10-28 2013-02-05 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
DE102009060194A1 (de) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Orale Darreichungsform umfassend Entecavir
US20120308652A1 (en) * 2009-12-23 2012-12-06 Daniela Stumm Oral form of administration comprising entecavir
WO2011103516A2 (en) * 2010-02-18 2011-08-25 The Trustees Of Princeton University Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
RU2012146101A (ru) 2010-03-31 2014-05-10 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
KR101439635B1 (ko) 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
IN2011CH03893A (no) * 2011-11-14 2015-08-21 Hetero Research Foundation
EP2644197A1 (en) * 2012-03-26 2013-10-02 Sanovel Ilac Sanayi ve Ticaret A.S. Novel Pharmaceutical Compositions of Entecavir
EP2644196B1 (en) * 2012-03-26 2019-09-18 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of Entecavir
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CN103908436B (zh) * 2012-12-29 2016-02-10 安徽贝克生物制药有限公司 一种速释型恩替卡韦组合物
KR101512895B1 (ko) 2013-08-09 2015-04-16 대화제약 주식회사 엔테카비어를 포함하는 약학적 조성물의 제조방법
WO2015194923A1 (ko) * 2014-06-20 2015-12-23 주식회사 씨티씨바이오 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법
EP3357515A4 (en) 2015-09-30 2019-06-19 Daicel Corporation COMPOSITION FOR SOLID PREPARATION EASY TO USE, EASY SOLID PREPARATION FOR USE COMPRISING SAID PARTICLE COMPOSITION
KR20230112817A (ko) 2022-01-21 2023-07-28 한림대학교 산학협력단 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
DE59710349D1 (de) * 1996-04-04 2003-07-31 Felix Specht Verfahren zur herstellung von gering dosierten freifliessenden und/oder direktkomprimierbaren pulversystemen
WO1998009964A1 (en) 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
WO2000009531A2 (en) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820417D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820416D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) † 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
EP1267880B2 (en) * 2000-02-29 2010-01-20 Bristol-Myers Squibb Company Low dose entecavir formulation and use

Also Published As

Publication number Publication date
ATE312613T1 (de) 2005-12-15
AR027965A1 (es) 2003-04-16
US6627224B2 (en) 2003-09-30
US20010033864A1 (en) 2001-10-25
DE60115870D1 (de) 2006-01-19
AU2001229775A1 (en) 2001-09-12
WO2001064221A1 (en) 2001-09-07
EP1267880B1 (en) 2005-12-14
PL201411B1 (pl) 2009-04-30
BRPI0108435B8 (pt) 2021-05-25
EA006181B1 (ru) 2005-10-27
HU230698B1 (hu) 2017-09-28
BG65815B1 (bg) 2010-01-29
BR0108435A (pt) 2004-06-15
DE60115870T3 (de) 2010-07-29
HUP0500558A3 (en) 2012-08-28
CO5261593A1 (es) 2003-03-31
SI1267880T1 (sl) 2006-06-30
NZ520024A (en) 2005-03-24
PL366102A1 (en) 2005-01-24
GEP20053504B (en) 2005-05-10
SK288008B6 (sk) 2012-10-02
BG106905A (bg) 2003-04-30
MY127422A (en) 2006-11-30
KR100757155B1 (ko) 2007-09-07
TWI287988B (en) 2007-10-11
EP1267880A1 (en) 2003-01-02
EE200200484A (et) 2004-04-15
JP5140222B2 (ja) 2013-02-06
SK11652002A3 (sk) 2003-09-11
EP1642582A1 (en) 2006-04-05
ES2253403T3 (es) 2006-06-01
DE60115870T2 (de) 2006-08-17
HRP20020649A2 (en) 2004-12-31
HK1048771A1 (zh) 2003-04-17
BRPI0108435B1 (pt) 2019-02-05
JP2004503467A (ja) 2004-02-05
EP1267880B2 (en) 2010-01-20
YU63002A (sh) 2005-03-15
HUP0500558A2 (hu) 2005-09-28
DK1267880T3 (da) 2006-03-06
ES2253403T5 (es) 2010-04-22
MXPA02008359A (es) 2003-02-12
SI1267880T2 (sl) 2010-04-30
CA2401569A1 (en) 2001-09-07
UA84534C2 (uk) 2008-11-10
KR20020082230A (ko) 2002-10-30
EA200200812A1 (ru) 2003-12-25
EG24408A (en) 2009-05-20
JP2015178523A (ja) 2015-10-08
PE20020770A1 (es) 2002-09-06
RS51561B (sr) 2011-08-31
DK1267880T4 (da) 2010-05-17
JP5921746B2 (ja) 2016-05-24
NO20024099D0 (no) 2002-08-28
IL150447A0 (en) 2002-12-01
NO324014B1 (no) 2007-07-30
CZ303395B6 (cs) 2012-08-29
JP2012255017A (ja) 2012-12-27
CA2401569C (en) 2009-08-18
EE05442B1 (et) 2011-08-15

Similar Documents

Publication Publication Date Title
NO20024099D0 (no) Lavdose entecavir-formulering og anvendelse
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
ITTO20010008A0 (it) Formulazione farmaceutica
DK1354888T3 (da) Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
ID30590A (id) Celana sekali pakai jenis-celana pendek
NO20020343D0 (no) Kaspase-inhibitorer og anvendelse derav
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
GB0101035D0 (en) Formulation and use thereof
NO20025158D0 (no) Lipidpreparat og anvendelse derav
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
PL372322A1 (en) Low dose liquid entecavir formulations and use
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
HK1040196A1 (zh) 低劑量艾替開韋製劑及其應用
NO20030156D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
NO20030547D0 (no) Azabicykliske derivater og deres terapeutiske anvendelse
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
GB0018887D0 (en) Compound and their therapeutic use
NO20025135D0 (no) Antihypertensive midler og anvendelse

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMI, CH

MK1K Patent expired